16 completed, 3 recruiting, 1 not yet recruiting, 1 terminated. 8 Phase 1, 6 Phase 3, 5 Not applicable, 5 Phase 2, 1 Phase 4.
Follow Neurogenic Detrusor Overactivity: new trials by email Literature Review of Neurogenic Detrusor Overactivity trials Research Report on Neurogenic Detrusor Overactivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TTNS in SCI Patients With Neurogenic Detrusor Overactivity TTNS - Spinal Cord Injuries, Neurogenic Detrusor Overactivity | Not applicable | Not yet recruiting | National University Hospital, Singapore | 12 | 2026-09-01 | 2026-08-25 |
| Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization EG110A - Neurogenic Detrusor Overactivity, Spinal Cord Injuries | Phase 1 / Phase 2 | Recruiting | Cyllene Therapeutics | 16 | 2025-01-08 | 2026-09-03 |
| Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury Epidural Spinal Cord Stimulation - Spinal Cord Injuries, Neuromodulation | Not applicable | Recruiting | University College, London | 20 | 2024-10-14 | 2025-03-14 |
| A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity mirabegron - Neurogenic Detrusor Overactivity | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 7 | 2024-02-28 | 2026-10-01 |
| Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction Standard number of injection sites, Reduced number of injection sites - Neurogenic Bladder, Lower Urinary Tract Symptoms | Not applicable | Completed | The Methodist Hospital Research Institute | 78 | 2023-10-04 | 2025-05-09 |
| Dorsal Genital Nerve Stimulation for Bladder Management After SCI Neuromodulation - Spinal Cord Injuries, Neurogenic Bladder | Not applicable | Unknown | University College, London | 10 | 2023-01-23 | 2024-04-26 |
| Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC Vibegron - Neurogenic Detrusor Overactivity | Phase 2 / Phase 3 | Recruiting | Urovant Sciences GmbH | 71 | 2022-10-12 | 2026-06-15 |
| Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B), Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B), Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) - Neurogenic Detrusor Overactivity | Phase 1 | Completed | Pfizer | 37 | 2020-06-26 | 2021-02-10 |
| BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG 4 mg Fesoterodine ER tablet from Zwickau, 4 mg fesoterodine ER tablet from Freiburg, 8 mg fesoterodine ER tablet from Zwickau - Neurogenic Detrusor Overactivity | Phase 1 | Completed | Pfizer | 18 | 2019-11-12 | 2021-05-07 |
| Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury Rec 0/0438 1 mg or Rec 0/0438 2 mg, placebo - Neurogenic Detrusor Overactivity | Phase 1 / Phase 2 | Completed | RECORDATI GROUP | 42 | 2018-06-07 | 2021-01-29 |
| Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury Trospium-Releasing Intravesical System (TAR-302-5018) - Neurogenic Detrusor Overactivity | Phase 1 | Completed | Taris Biomedical LLC | 7 | 2017-04-24 | 2020-01-13 |
| Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity Mirabegron - Neurogenic Detrusor Overactivity | Phase 3 | Completed | Astellas Pharma Europe B.V. | 91 | 2016-06-17 | 2024-11-12 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) mirabegron - Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 1 | Completed | Astellas Pharma Europe B.V. | 9 | 2015-12-17 | 2024-10-31 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder Mirabegron - Neurogenic Detrusor Overactivity, Overactive Bladder | Phase 1 | Completed | Astellas Pharma Inc | 34 | 2014-09-21 | 2024-10-22 |
| Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury? Spinal Cord Injury, Neurogenic Detrusor Overactivity | Completed | Swiss Paraplegic Research, Nottwil | 47 | 2013-11-01 | 2015-11-17 | |
| A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) Solifenacin succinate - Neurogenic Detrusor Overactivity, Pediatric | Phase 3 | Completed | Astellas Pharma Europe B.V. | 23 | 2013-09-25 | 2024-10-31 |
| A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity Solifenacin succinate - Neurogenic Detrusor Overactivity | Phase 3 | Completed | Astellas Pharma Europe B.V. | 76 | 2012-08-14 | 2024-11-14 |
| Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder Solifenacin succinate suspension 5 mg - Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 1 | Completed | Astellas Pharma Inc | 14 | 2012-03-13 | 2024-10-22 |
| Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients external electric pudendal nerve stimulation - Neurogenic Detrusor Overactivity, Spinal Cord Injury | Not applicable | Withdrawn | Ulrich Mehnert | 2009-12-01 | 2019-07-23 | |
| Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years Fesoterodine - Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 2 | Completed | Pfizer | 21 | 2009-03-01 | 2011-11-24 |
Showing 20 of 23. Sign in to see all of them.
Spinal Cord Injuries (9) · Urinary Bladder, Overactive (6) · Urinary Bladder, Neurogenic (3) · Meningomyelocele (2) · Cone-Rod Dystrophies (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lower Urinary Tract Symptoms (1) · Meningocele (1) · Myelitis, Transverse (1) · Neurogenic Bowel (1) · Spinal Dysraphism (1) · Wounds and Injuries (1)
Nervous System Diseases (10) · Central Nervous System Diseases (9) · Pathological Conditions, Signs and Symptoms (9) · Spinal Cord Diseases (9) · Trauma, Nervous System (9) · Wounds and Injuries (9) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Male Urogenital Diseases (8) · Signs and Symptoms (8) · Urinary Bladder Diseases (8) · Urogenital Diseases (8) · Urologic Diseases (8) · Urological Manifestations (6) · Lower Urinary Tract Symptoms (5)
mirabegron (4) · Solifenacin Succinate (3) · darifenacin (2) · Botulinum Toxins, Type A (1) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (1) · Transcutaneous Electric Nerve Stimulation (1) · fesoterodine (1)
Astellas Pharma Europe B.V. (4) · Pfizer (3) · Astellas Pharma Inc (2) · University College, London (2) · Astellas Pharma Global Development, Inc. (1) · Cyllene Therapeutics (1) · National University Hospital, Singapore (1) · RECORDATI GROUP (1) · Sunnybrook Health Sciences Centre (1) · Swiss Paraplegic Research, Nottwil (1) · Taris Biomedical LLC (1) · The Methodist Hospital Research Institute (1) · Toronto Rehabilitation Institute (1) · Ulrich Mehnert (1) · Urovant Sciences GmbH (1)
Poland (9) · Belgium (8) · United States (8) · Denmark (6) · Philippines (5) · Canada (4) · Turkey (Türkiye) (4) · United Kingdom (4) · Serbia (3) · South Korea (3) · Croatia (2) · Jordan (2) · Latvia (2) · Lithuania (2) · Malaysia (2)
Cornelia Haag-Molkenteller, MD (1) · Francisco Cruz, M.D. (1) · Gobinathan Chandran, MBBS (1) · Herman Ellman, MD (1) · Janet Owens-Grillo (1) · Lynsey Duffell, PhD (1) · Magdy Hassouna, MD (1) · Martin Schubert, MD (1) · Michael Kennelly, MD (1)
PMID 32007426, PMID 33231929, PMID 34058027, PMID 36892754, PMID 40836399
2014 (2), 2015 (2), 2017 (1), 2019 (1), 2023 (1)